These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18339181)

  • 41. Plasma chitotriosidase activity in patients with beta-thalassemia.
    Barone R; Di Gregorio F; Romeo MA; Schilirò G; Pavone L
    Blood Cells Mol Dis; 1999 Feb; 25(1):1-8. PubMed ID: 10349508
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Screening for lysosomal diseases in a selected pediatric population: the case of Gaucher disease and acid sphingomyelinase deficiency.
    Di Rocco M; Vici CD; Burlina A; Venturelli F; Fiumara A; Fecarotta S; Donati MA; Spada M; Concolino D; Pession A
    Orphanet J Rare Dis; 2023 Jul; 18(1):197. PubMed ID: 37480063
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Determination of oligosaccharides and glycolipids in amniotic fluid by electrospray ionisation tandem mass spectrometry: in utero indicators of lysosomal storage diseases.
    Ramsay SL; Maire I; Bindloss C; Fuller M; Whitfield PD; Piraud M; Hopwood JJ; Meikle PJ
    Mol Genet Metab; 2004 Nov; 83(3):231-8. PubMed ID: 15542394
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy.
    Vedder AC; Cox-Brinkman J; Hollak CE; Linthorst GE; Groener JE; Helmond MT; Scheij S; Aerts JM
    Mol Genet Metab; 2006 Nov; 89(3):239-44. PubMed ID: 16765076
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Type 1 Gaucher disease: null and hypomorphic novel chitotriosidase mutations-implications for diagnosis and therapeutic monitoring.
    Grace ME; Balwani M; Nazarenko I; Prakash-Cheng A; Desnick RJ
    Hum Mutat; 2007 Sep; 28(9):866-73. PubMed ID: 17464953
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CCL18: a urinary marker of Gaucher cell burden in Gaucher patients.
    Boot RG; Verhoek M; Langeveld M; Renkema GH; Hollak CE; Weening JJ; Donker-Koopman WE; Groener JE; Aerts JM
    J Inherit Metab Dis; 2006 Aug; 29(4):564-71. PubMed ID: 16736095
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mass spectrometry in the study of lysosomal storage disorders.
    Meikle PJ; Fuller M; Hopwood JJ
    Cell Mol Biol (Noisy-le-grand); 2003 Jul; 49(5):769-77. PubMed ID: 14528914
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Lysosomal storage disorders. Is the natural history of the disease changing?].
    Giraldo P; Pocoví M
    Med Clin (Barc); 2008 Mar; 130(7):259-60. PubMed ID: 18355426
    [No Abstract]   [Full Text] [Related]  

  • 49. Chitotriosidase variants in patients with Gaucher disease. Implications for diagnosis and therapeutic monitoring.
    Irún P; Alfonso P; Aznarez S; Giraldo P; Pocovi M
    Clin Biochem; 2013 Dec; 46(18):1804-7. PubMed ID: 24060732
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biomarkers for Lysosomal Storage Disorders with an Emphasis on Mass Spectrometry.
    Mashima R; Okuyama T; Ohira M
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32295281
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma chitotriosidase in lysosomal storage diseases.
    Isman F; Hobert JA; Thompson JN; Natowicz MR
    Clin Chim Acta; 2008 Jan; 387(1-2):165-7. PubMed ID: 17869233
    [No Abstract]   [Full Text] [Related]  

  • 52. Detecting multiple lysosomal storage diseases by tandem mass spectrometry--a national newborn screening program in Taiwan.
    Liao HC; Chiang CC; Niu DM; Wang CH; Kao SM; Tsai FJ; Huang YH; Liu HC; Huang CK; Gao HJ; Yang CF; Chan MJ; Lin WD; Chen YJ
    Clin Chim Acta; 2014 Apr; 431():80-6. PubMed ID: 24513544
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.
    Hollak CE; van Weely S; van Oers MH; Aerts JM
    J Clin Invest; 1994 Mar; 93(3):1288-92. PubMed ID: 8132768
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plasma lipids are altered in Gaucher disease: biochemical markers to evaluate therapeutic intervention.
    Meikle PJ; Whitfield PD; Rozaklis T; Blacklock D; Duplock S; Elstein D; Zimran A; Mengel E; Cannell P; Hopwood JJ; Fuller M
    Blood Cells Mol Dis; 2008; 40(3):420-7. PubMed ID: 18054258
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison between the biochemical properties of plasma chitotriosidase from normal individuals and from patients with Gaucher disease, GM1-gangliosidosis, Krabbe disease and heterozygotes for Gaucher disease.
    Wajner A; Michelin K; Burin MG; Pires RF; Pereira ML; Giugliani R; Coelho JC
    Clin Biochem; 2007 Mar; 40(5-6):365-9. PubMed ID: 17291472
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy.
    Meikle PJ; Ranieri E; Simonsen H; Rozaklis T; Ramsay SL; Whitfield PD; Fuller M; Christensen E; Skovby F; Hopwood JJ
    Pediatrics; 2004 Oct; 114(4):909-16. PubMed ID: 15466084
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Extracellular matrix components: an intricate network of possible biomarkers for lysosomal storage disorders?
    Batzios SP; Zafeiriou DI; Papakonstantinou E
    FEBS Lett; 2013 Apr; 587(8):1258-67. PubMed ID: 23454643
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of two approaches to lysosomal acid lipase deficiency patient identification: An observational retrospective study.
    Cebolla JJ; Irún P; Mozas P; Giraldo P
    Atherosclerosis; 2019 Jun; 285():49-54. PubMed ID: 31004967
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Osteopontin: a potential biomarker of Gaucher disease.
    Vairo F; Sperb-Ludwig F; Wilke M; Michellin-Tirelli K; Netto C; Neto EC; Schwartz I
    Ann Hematol; 2015 Jul; 94(7):1119-25. PubMed ID: 25875742
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical evaluation of biomarkers in Gaucher disease.
    Deegan PB; Cox TM
    Acta Paediatr Suppl; 2005 Mar; 94(447):47-50; discussion 37-8. PubMed ID: 15895712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.